

# Index

- Aceperone, 95, 96  
Acetylcholine, 25, 60, 220  
    effects of drugs on turnover rate  
    in striatum and occipital cortex, 221  
Acetylcholinesterase, 220  
*N*-Acetyl-4-desmethylnescaline, 194  
*N*-Acetyl-3-4-dimethoxyphenethylamine,  
    193  
*N*-Acetyl-3-hydroxy-4-methoxyphenethyl-  
    amine (iso-NAMT), 193  
*N*-Acetyl-3-methoxy-4-hydroxyphenethyl-  
    amine (n-NAMT), 193  
ACTH, 12  
    dopamine- $\beta$ -hydroxylase, 16  
*S*-Adenosylmethionine, 189  
Adenylate cyclase, 16  
    effects of drugs on, 217  
    in striatum, 216  
Adrenaline (see epinephrine)  
Afferent terminals, 70  
Alcohol dehydrogenase, 20  
Aldehyde dehydrogenase, 23  
Aldehyde oxidase, 20  
 $\gamma$ -Aminobutyric acid, 60, 76  
8-Amino-1,2-methanoindane chloride, 14  
Amphetamine  
    hydroxy derivate, 210  
    isomers, cardiovascular effects, 178  
    various actions of, 26, 31, 45, 48, 49,  
        50, 51, 52, 90, 96, 98, 99, 172,  
        173, 178, 210, 218  
Amygdala, 151  
    Electrode implantation in, 113  
    Stimulation of, 153  
Anterior funiculus, 3  
Apomorphine, 32, 45, 48, 94, 191, 215,  
    217, 219  
    behavioral activation and stereotypy in-  
        duced by, 89  
    in lesioned animals, 52  
    stimulation of catecholamine receptors,  
        49  
Aquayamycin, 12  
Ascorbic acid, 191  
ATP, 6  
Basal ganglia (see specific nuclei)  
    electrode implantation in, 113  
Barbiturates, 23  
Behavior  
    abnormal movements, 65  
    avoidance conditioning, 64  
    caudate stimulation, 64  
    chemical stimulation, 65  
    delayed-response task, 63  
    hyperactivity, 51  
    stereotypy, 89, 90, 98, 99  
    striatal lesions, 63  
    thalamic lesions, 63  
    visuomotor integration, 62  
Behavioral regulation, role of basal ganglia  
    in, 60  
Benztropine, 219  
Benzylamine  
    as substrate for MAO, 21  
Benzylhydrazines, 29  
Benzylxyamines, 11, 29  
Bethanidine, 31  
Biopterin, 15

- Blood brain barrier, 29  
 Borohydride, 11  
 Bufotenin, 188, 190  
 Butylgallate, 21  
 Butyrophenones, 32, 45
- Capsula interna, 202
- Catecholaminergic system, 3 (see also dopaminergic system)  
 in human fetal brain, 2
- Catecholamines  
 alcohol derivatives, 22  
 assay methods, 2, 4, 5  
 biosynthesis, 7, 8  
 deaminated metabolites, 17  
 definition of, 1  
 localization by, 2-6  
 electron microscopy, 6  
 histofluorescence, 2  
 immunocytochemistry, 3  
 subcellular fractionation, 6  
 methylated metabolites, 17, 190  
 in neostriatum, 59  
 regional distribution of, 2  
 in synaptosomes, 6  
 turnover, 24  
 uptake, 26
- Catechol-O-methyltransferase (COMT), 17, 20, 190  
 inhibition of, 21, 31  
 isoenzymes of, 20
- Caudate nucleus, 42, 72, 130 (see also striatum)  
 dopamine and HVA levels in  
 Huntington's disease, 46  
 Parkinsonism, 44  
 electrode implantation in, 113  
 functional properties, 71  
 inhibitory action of, 74  
 response to tests after L-Dopa and iprazid, 129  
 in sensory convergence, 74  
 stimulation of, 153  
 in visuomotor integration, 62
- Central nervous system disease  
 definition of, 111  
 electrode implantation for diagnosis and treatment of, 112
- Central neuronal modulation, role of basal ganglia in, 60
- Centrum medianum, 69, 132  
 Cerebral cortex, 202  
 Chlorpromazine, 52, 170  
 prolonged treatment with, 110  
 Choline acetylase, 220  
 Choreoathetosis, 167  
 Clonidine, 32, 48, 50  
 Clozapine, 32, 219  
 Cocaine, 26  
 Conjugation in brain, 23  
 Corazol, 114, 137, 141  
 Corpus striatum  
 behavioral studies, 61  
 3',5'-cyclic adenosine monophosphate, 213  
 2-Cyclohexylcyclopropaneamine, 14  
 Cyclopropylamine, 22  
 Cysteine, 12  
 Cytochemical techniques, 3
- Depression, 101  
 endogenous, 101
- Deserpidine, 30
- Desmethylinipramine, 26, 30  
 4-Desmethylnescaline, 194  
 Dexamethasone, 16  
 Dezeril, 114, 127, 129, 133, 147  
 pharmacological tests with, 141
- Dibutylryl cyclic AMP, effect on catecholamine synthesis, 16
- Dichloromercuribenzoate, 21
- Diencephalon, 66  
 striatal influence on, 73
- N*-Diethylmaleimide, 11
- 3,4-Dihydroxyamphetamines, 20  
 3,4-Dihydroxyephedrine, 20  
 3,4-Dihydroxymandelic acid, 20  
 as substrate for COMT, 20  
 3,4-Dihydroxyphenylacetaldehyde, 17  
 Dihydroxyphenylacetamide, 21  
 3,4-Dihydroxyphenylacetic acid (DOPAC), 17, 213  
 as substrate for COMT, 20  
 3,4-Dihydroxyphenylalanine (see Dopa)  
 3,4-Dihydroxyphenylethanol (DOPET), 17  
 3,4-Dihydroxyphenylglycol (DOPEG), 17  
 3,4-Dihydroxyphenylglycolaldehyde, 17  
 3,4-Dimethoxyphenethylamine (DMPEA), 188, 190  
 effects of, 187  
 6,7-Dimethyltetrahydropterin (DMPH<sub>4</sub>), 10

- DMPH<sub>4</sub> (*cont'd*)  
 tyrosine hydroxylase, 15  
*N,N*-Dimethyltryptamine, 187, 188, 190  
 Diphenylhydantoin, 191  
 Disulfiram, 23, 29, 49  
 Dithiothreitol, 12  
 Dopa (L-Dopa), 6, 10, 29, 43, 45, 50, 101, 114, 115, 122, 127, 136, 141, 147, 173, 217  
 behavioral activation from, 89  
 concentration in striatum, 207, 208  
 dyskinesias and, 46  
 effect on memory, 132  
 effect on motor activity, 50  
 effect on neuronal activity, 131  
 excretion of, 147  
 inhibition on tyrosine hydroxylase, 15  
 and iprazid, 113, 114, 129  
*O*-methylation of, 20  
 pharmacological tests with, 141  
 urine levels  
 in epilepsy, 113  
 in Parkinsonism, 113  
 Dopa decarboxylase, 10, 42, 211  
 inhibitors of, 11  
 pig kidney, 10  
 regulation of biosynthesis, 15  
 vitamin B deficiency, 10  
 Dopamine, 1, 2, 14, 16, 17, 22, 23, 24, 30, 31, 41, 42, 60, 64, 68, 76, 90, 97, 101, 110, 115, 122, 135, 188, 190  
 association with mania and depression, 100  
 biosynthesis of, 205  
 catabolism of, 18  
 concentration in brain nuclei or other neural tissue, 203  
 excretion of,  
 after corazol treatment, 146  
 after L-Dopa treatment, 147  
 hypothesis in schizophrenia, 168  
 as substrate for COMT, 20  
 as substrate for MAO, 21  
 measurement of turnover rate, 202  
 in the striatum, 211  
*p*-methylation of, 21  
 nigrostriatal pathway  
 in Parkinson's disease, 43  
 regulation of turnover rate in brain, 201  
 release by nigral stimulation, 75  
 and stereotyped thinking, 99  
 storage forms in the striatum, 208  
 Dopamine (*cont'd*)  
 urine levels  
 in Parkinsonism, 113  
 in epilepsy, 113  
 Dopamine- $\beta$ -hydroxylase, 3, 9, 11  
 activity in cervical ganglion and mesenteric artery of rats, 16  
 in adrenal gland and synaptic vesicles of the splenic nerve, 6  
 ascorbic acid deficiency, 12, 16  
 inhibitors of, 12, 29  
 in plasma, 12  
 in stress, 12, 16  
 Dopaminergic system, 205  
 effect of drugs on, 214, 217, 218  
 interaction with other neuronal systems, 220, 221  
 mesolimbic, 218  
 nigrostriatal, 3, 91, 218  
 synapse in, 222  
 site of action of various drugs, 222  
 Dopastin, 12  
 Dorsal noradrenaline bundle, 3  
 Drug-induced extrapyramidal side effects  
 and relationship to outcome, 169  
 Dyskinesia, 61, 167  
 L-dopa-induced, 46  
 tardive, 47  
 Dysphoria, 175  
 Dystonia, 167  
 Efferent projections of striatum, 70  
 Efferent terminals, 70  
 Electric shocks, 148  
 effects of amphetamine on, 93  
 Electrical anodal polarizations (EP), 153, 155  
 Electrical stimulation (ES), 155  
 Electrical treatments, 113  
 Electroconvulsive therapy, 101  
 Electroencephalogram (EEG), 112, 136, 141, 148  
 Electron microscopy, 3, 4  
 Electron transport system, 191  
 Electrophysiological studies, 71, 75  
 Electrosyncorticotogram (ESCoG), 113, 137, 141  
 Emotional responses, 135  
 Entopeduncular nucleus, 75  
 Environmental factors and stereotypy, 97  
 Enzymatic radiochemical methods, 5

- Enzymes of catecholamine biosynthesis, 9
- Epilepsy, 133
- EEG patterns in, 136
- electrosubcorticogram (ESCoG), 136
- implanted electrode, 147
- neurophysiological studies of, 113, 114
- Epileptiform changes, 151, 153
- Epileptogenic focus, 137, 148
- Epinephrine, 1, 2, 6, 9, 12, 14, 17, 20, 26, 110, 115, 136, 189
- in adrenal gland, 7
- excretion after L-dopa administration, 147
- levels in central nervous system, 6
- as substrate for COMT, 20
- as substrate for MAO, 21
- olfactory bulb and tubercule, 6
- urine levels
- in epileptic patients, 113
- in Parkinsonian, 113
- N*-Ethyl maleimide, 12
- Euphoria, 101, 173
- Excitation, 65, 72, 95, 96
- Excretion curves, 115
- Excretion of
- dopa, 115, 146
- dopamine, 141, 115
- epinephrine, 115, 141
- 5-HIAA, 115, 146
- norepinephrine, 115, 146
- Extrapyramidal motor function, 77, 131
- disorders, 167
- side effects (EPS), 169, 219
- FAD, 22
- False transmitters, 11, 31
- Feedback control mechanism, 211
- Firing rate, 121, 132, 133
- First-order rate constant, 206
- FLA-63, 95
- Flexor reflex, 53
- Fluorometric techniques, 4
- Fluphenazine, 101
- Freeze-blowing, 207
- Freeze-etching, 3
- Frontal lobe, 62
- Functional impairment, 94
- Functional localization, 71, 100
- Fusaric acid, 12
- Globus pallidus, 66, 73, 75, 202, 220
- dezeril, response to, 130
- L-Dopa, response to, 132
- Glutathion (e), 12
- Glycuronyltransferase, 20
- Golgi apparatus, 3
- Grooming, 93
- Guaiacol-*O*-methyltransferase (GOMT), 192
- O*-methylation by, 193
- in rat liver, 195
- response to stress, 195
- Guaiacols, 191
- Guanethidine, 31
- Guanisoquine, 31
- Haloperidol, 46, 49, 52, 100, 101, 215, 218, 219
- Harmaline, 22
- Hippocampus, 151
- electrode implantation in, 113
- stimulation of left hippocampus, 153
- Histamine, 21
- Histidine, 10
- Histofluorescence method for detecting catecholamines, 2
- Homovanillic acid (HVA), 17, 42, 219
- in cerebral spinal fluid from depressed and manic patients, 100
- iso-Homovanillic acid, 20, 193
- Huntington's disease, 41, 45
- Hydantoin, 23
- Hydrazines, 11
- 3-Hydroxybenzylhydrazine, 211
- $\gamma$ -Hydroxybutyrolactone, 211
- 6-Hydroxydopamine, 3, 10, 12, 51
- 5-Hydroxyindolacetic acid (5-HIAA), 113, 114, 122, 141
- excretion after corazol treatment, 146
- excretion after L-dopa treatment, 147
- excretion after dezeril treatment, 147
- urine levels
- in epilepsy, 113
- in Parkinsonism, 113
- Hydroxyindole-*O*-methyltransferase, 193
- 3-Hydroxy-4-methoxyphenethylamine, 188
- 4-Hydroxy-3-methoxyphenylacetaldehyde, 17
- 4-Hydroxy-3-methoxyphenylethanol (MOPET), 17

- 4-Hydroxy-3-methoxyphenylethylamine, 17
- 4-Hydroxy-3-methoxyphenylglycolaldehyde, 17
- 5-Hydroxytryptamine (5-HT), 28, 42
- 5-Hydroxytryptophan(e) (5-HTP), 10, 44
- 5-Hydroxytryptophan(e) decarboxylase, 10
- Hyperactivity of the striatal dopamine system and tardive dyskinesia, 48
- Imipramine, 26
- Impulse activity (IA), 113
- Inactivation of catecholamines, 17
- Indol(e) amines, 2  
as substrate for MAO, 21
- Inhibition, 65
- Interpeduncular nucleus, 3
- Iodophenol-*O*-methyltransferase, 193
- Iodotyrosine, 28
- Iproniazid, 22, 28
- Iron, 9
- Kinetics, 9, 22, 209, 211, 214, 215  
tyrosine hydroxylase, 9
- $K_m$  tyrosine hydroxylase cofactor, 9
- Lateral funiculus, 3
- Level of relatively stable function (LRSF), 118, 130
- Lithium, 30
- Locus coeruleus, 3  
in Parkinson's disease, 42
- LSD-25, 110
- Mercaptoethanol, 12
- Mescaline, 110, 187, 188, 190
- Mesencephalon, 66
- Metamyzil, 114, 127, 129
- Metanephrine, 12, 16, 195
- Metaraminol, 31
- Methamphetamine, 99
- Methionine, 190
- Methiothepin, 215
- 3-Methoxy-4,5-dihydroxy-*N,N*-dimethylphenethanolamine, 196
- 3-Methoxy-4,5-dihydroxy-*N*-methylphenethanolamine, 196
- 3-Methoxy-4,5-dihydroxyphenethanol, 196
- 3-Methoxy-4,5-dihydroxyphenethylamine, 196
- 3-Methoxy-4-hydroxymandelic acid, 189
- 3-Methoxy-4-hydroxyphenethanol, 195
- Methoxyhydroxyphenylethanol, 23
- iso-Methoxytyramine, 193
- $\alpha$ -Methyl-dopa, 10, 11, 31
- $\alpha$ -Methyl-dopamine, 11, 31
- Methylhistamine  
as substrate for MAO, 21
- N*-Methylmetanephrine, 195
- $\alpha$ -Methylnoradrenaline, 31
- $\alpha$ -Methyloctopamine, 31
- 6-Methyltetrahydropterin, 9
- 7-Methyltetrahydropterin, 10
- $\alpha$ -Methyl-*m*-tyramine, 31
- $\alpha$ -Methyl-*m*-tyrosine, 31
- $\alpha$ -Methyl-*p*-tyrosine, 10, 24, 28, 29, 46, 49, 50, 101  
in biphasic decay of striatal DA, 210  
effects on brain catecholamine concentrations, 44
- Methysergide bimalenate, 114
- Microwave radiator, 208
- Midbrain tegmentum, 113, 155
- Monoamine oxidase (MAO), 17, 21, 31  
form A and form B, 22  
inhibitors of, 22, 29
- MOPEG-SO<sub>4</sub>, 23
- Morphine, 217  
on behavior in rats and mice, 95  
behavioral activation and stereotypy induced by, 94
- Motor cortex, 66
- NADPH, 7
- Neocortex, 69  
stimulation of, 72
- Neostriatum, 60  
neuronal composition of, 70
- Neuroleptics, 44, 45, 61, 97
- Nialamide, 53
- Noradrenaline (see norepinephrine)
- p*-OH-norephedrine, 210
- Norepinephrine, 1, 2, 9, 12, 14, 17, 22, 23, 24, 28, 41, 42, 95, 101, 115, 122, 135,

- Norepinephrine (*cont'd*)  
 in adrenal, 7  
 biological assay, 1  
 in brain and other neural tissues, 203  
 catabolism of, 18  
 distribution, 5  
 drugs acting on storage of, 31  
 drugs acting on uptake of, 30  
 drugs and release of, 31  
 excretion after corazol treatment, 146  
 excretion after L-dopa administration, 147  
 L-isomers, 27  
 localization, 6  
 in spinal cord, 53  
 as substrate for COMT, 20  
 as substrate for MAO, 21  
 uptake of, 24, 25  
 urine levels  
   in epilepsy, 113  
   in Parkinsonism, 113
- Normetanephrine, 12, 17, 22, 23  
 Nortriptyline, 30  
 Nucleus accumbens, 202, 212  
   turnover rate of dopamine in, 219  
 Nucleus amygdaloideus centralis, 202, 212  
 Nucleus arcuatus hypothalami, 201  
 Nucleus caudatus putaman, 202, 212  
 Nucleus dorsalis medialis hypothalami, 201  
 Nucleus periventricularis, 201
- Octopamine, 12, 13, 31  
 Olfactory bulbs, 13  
 Olfactory system, 6  
 Ouabain, 16  
 Oxazolidinediones, 23  
 Oxygen, 9, 15, 22
- Pallidum, response to tests after L-dopa  
   and iprazid, 129  
 Paralysis agitans, 61  
 Pargyline, 22  
 Parkinson's disease, 41, 59, 109, 112,  
   "Aubert task" test in, 62  
   cerebral and striatal dopamine levels in, 6  
   neurophysiological studies in, 113  
   symptomatology of, 42  
 Pars compacta, 76, 201  
 Pediphen, 114, 127, 130, 131
- Perceptual function, role of basal ganglia  
   in, 60  
 Phenol-O-methyltransferase, 193  
 Phenolsulfotransferase, 20, 23  
 Phenothiazines, 23, 32, 45, 50, 61, 169  
 Phenoxybenzamine, 26, 52, 53, 95, 96  
 Phenylalanine, 7  
 Phenylethanolamine N-methyltransferase  
   (PNMT), 6, 7, 12, 14  
   inhibitors, 13  
   localization, 13  
 Phenylethylamines, 7  
 Phosphoadenosine-5-phosphosulfate, 23  
 Picolinic acid, 29  
 Picrotoxin, 74  
 Pimozide, 49, 98, 101  
 Potassium, 16, 25  
 Potassium chloride,  
   intracaudate injections of, 64  
 Prolactin, 189  
 Propranolol, 52  
 Propylgallate, 21  
 Protryptiline, 30  
 Psychosis, amphetamine induced, 172, 173  
 Putamen, 42, 46, 72, 76  
 Pyrazole, 23  
 Pyrogallol, 21, 30
- Q, coenzyme, 191
- Raynaud's disease, 112  
 Rescinnamine, 30  
 Reserpine, 28, 30, 46, 49, 50, 52, 53, 173,  
   181, 213  
   effect on brain catecholamine concentra-  
   tion, 44  
   prolonged treatment with, 110
- Saline  
   and striatal concentrations of cAMP, 217  
   and turnover rate of acetylcholine in stri-  
   atum and occipital cortex, 221
- Schizophrenia  
   abnormal movements in, 167  
   amphetamine psychosis, 99  
   MAO inhibitors, 172  
   stereotyped behavior in, 98

- Sensorimotor integration, role of basal ganglia in, 60
- Serotonin, 60, 101, 110, 188, 190
- Slow electrical processes (SEP), 113, 130
- Spinal cord, 5, 23, 53
- Spleen, 5
- Splenic nerve, 5, 6
- Stereotypy
  - amphetamine-induced, 49, 98, 99
  - apomorphine-induced, 89
  - definition of, 90
- Stimulation
  - frequency of and the release of noradrenaline, 25
  - of the neocortex, 72
- Striatum
  - acetylcholine in, 221
  - afferent projections of, 66
  - efferent projections of, 66
  - etiology of schizophrenia, 60
  - lesions of and disturbances of learned behavior, 63
  - measurement of dopa concentrations in, 207
  - unilateral lesion of, 52
- Strychnine, 74
- Substantia nigra, 66, 201, 220
  - dopamine in, 68
  - in Huntington's disease, 46
  - in Parkinson's disease, 42
  - unilateral lesions of, 51
- Synapse
  - dopaminergic, site of action of various drugs, 222
- Synaptic vesicles
  - localization of dopamine- $\beta$ -hydroxylase, 11
  - storage of noradrenaline and acetylcholine in, 25
- Synaptosomes, 14
- Synephrine, 12, 13
- Tardive dyskinesia and hyperactivity of the striatal dopamine system, 48
- Telencephalon, 66, 202
- Tetrabenamine, 46, 53
- Tetrahydrobiopterine, 14, 15
- Thalamic nuclei
  - electrode implantation in, 113
- Thalamus, 66
- Therapeutic response, relationship to extrapyramidal side effects, 169
- Thioridazine, 219
- Tranlycypromine, 14
- Tremography, 170,
  - usefulness of, 182
- Trifluoperazine, 170
- 3,4,5-Trimethoxyphenylethylamine, 21
- Tropolones, 29, 30
- Tryptamine, 190
- Tryptophan, 10
- Tuberculum olfactorium, 202, 212
- Tyramine, 9, 13, 23
- Tyrosine, 7, 9, 10, 16
  - biosynthesis in mammals, 7
  - and tyrosine hydroxylase, 15
- Tyrosine hydroxylase, 42, 68
  - in brain, 9
  - in the central nervous system, sympathetic ganglia and the adrenal glands, 9
  - inhibitors of, 14, 28
  - in vitro inhibition by dopamine, 215
  - oxygen utilization, 15
  - regulation of biosynthesis, 14
  - regulation in striatum, 213
- Ubiquinone, 191
- Uncus, 151
  - electrode implantation in, 113
- Unilateral lesions, 51, 61
- iso-Vanillin, 193
- iso-Vanillyl alcohol, 193
- Vanilmandelic acid (VMA), 17
  - localization of, 20
- Ventral noradrenaline bundle, 3
- Ventrolateral thalamic nucleus (VTN)
  - response to tests after L-dopa and iprazid, 130
- Visuomotor integration, 62
- Vitamin B deficiency,
  - dopa decarboxylase activity, 10
- Zona compacta, 3